DAIICHI SANKYO S/ADR (DSNKY) analyst actions
DSNKY analyst actions moved a median of -0.21% by the close. Rating and price-target actions on DSNKY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DSNKY overview →
11 measured DSNKY analyst action events.
| Middle 50% of DSNKY analyst action reactions | -2.18% to +0.82% |
|---|---|
| Median reaction (to close) | -0.21% |
| Measured reactions | 11 |
Half of the 11 DSNKY analyst action events with a measured close landed between -2.18% and +0.82%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer | Press release | -0.08% | -1.33% | |
| TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer | Press release | +0.00% | -2.83% | |
| DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer | Press release | +2.39% | +2.15% | |
| DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer | Press release | +0.38% | +1.58% | |
| DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer | Press release | -2.71% | -3.60% | |
| DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | Press release | -0.04% | +0.45% | |
| DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer | Press release | +0.00% | -0.08% | |
| TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse | Press release | -0.46% | -0.21% | |
| QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML | Press release | +0.00% | -1.53% | |
| Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer | Press release | +0.00% | -3.85% | |
| Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Press release | +0.00% | +1.20% |
More DSNKY: earnings → · SEC filings → · DSNKY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOTRICITY INC (BTCY) | 124 | 0.00% | 38% |
| CLEMENTIA PHARMACEUTICALS INC COMMON SHARES (CMTA) | 124 | +0.03% | 51% |
| LIANLUO SMART LTD COMMON (LLIT) | 123 | -0.98% | 28% |
| Medite Cancer Diagnostics, Inc. (MDIT) | 123 | 0.00% | 2% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.